血清型不确定性对成人肺炎球菌疫苗选择的影响:信息价值分析
该分析评估美国65岁及50-64岁队列中成人肺炎球菌疫苗选择的信息价值,比较不同疫苗策略。但21价肺炎球菌结合疫苗血清型发病率的部分完美信息期望值在两个年龄组均较低,支持无论血清型不确定性如何均可使用该疫苗。
要点
- 21价肺炎球菌结合疫苗血清型发病率的部分完美信息期望值较低,支持其使用。
- 信息价值结果更支持65岁人群而非50岁人群的进一步研究。
核心结论
- 信息价值结果更支持65岁人群特定参数的进一步研究,而非50岁人群。
- 21价肺炎球菌结合疫苗血清型发病率的部分完美信息期望值在两个年龄组均较低,支持成人使用该疫苗 regardless of serotype uncertainty。
研究设计与样本
- 基于美国65岁和50-64岁队列的决策分析模型,比较成人肺炎球菌疫苗。
- 模型参数包括美国数据的疫苗血清型特异性肺炎球菌疾病和死亡风险、已发表文献的接种率、临床试验和Delphi小组估计的疫苗效力。
- 分析估计完美信息期望值和部分完美信息期望值,支付意愿阈值为每获得一个质量调整生命年0至20万美元。
- 数据收集和分析于2024年进行。
主要发现
- 65岁人群信息价值估计在每QALY 10万美元阈值下最高,更高阈值下明显降低。
临床怎么用
- 对于65岁成人,可优先使用21价肺炎球菌结合疫苗,因血清型不确定性对决策影响有限。
- 针对65岁人群的肺炎球菌疾病死亡和残疾参数及疫苗效力参数的进一步研究可能具有较高价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Potential public health effects of adult pneumococcal vaccines are uncertain because of observed changes in pneumococcal serotype epidemiology. Prior analyses favored the 21-valent pneumococcal conjugate vaccine but observed that serotype changes in some populations could decrease its favorability. Value of information analysis could guide further research to clarify uncertainty. METHODS: Analyses evaluated value of information in U.S. cohorts aged 65 years, comparing adult pneumococcal vaccines. Model parameters included vaccine serotype-specific pneumococcal disease and mortality risks from U.S. data, vaccination rates from published literature, and vaccine effectiveness from clinical trials and Delphi panel estimates. Analyses estimated expected value of perfect information and expected value of partial perfect information at willingness-to-pay thresholds from $0 to $200,000 per quality-adjusted life year gained. A secondary analysis examined those aged 50-64 years. Data were collected and analyzed in 2024. RESULTS: In those aged 65 years, value of information estimates were highest at the $100,000/quality-adjusted life year gained threshold and were markedly less at higher thresholds. At $100,000/quality-adjusted life year gained, population expected value of perfect information was $178.1 million; expected value of partial perfect information for pneumococcal disease mortality and disability parameters combined was $89.6 million and for vaccine effectiveness parameters was $73.8 million. The 21-valent pneumococcal conjugate vaccine serotype incidence expected value of partial perfect information was $19 million. In those aged 50-64 years, expected value of partial perfect information for vaccine effectiveness was $2.9 million and for 21-valent pneumococcal conjugate vaccine serotype incidence was $139,080. CONCLUSIONS: Value of information results were more supportive of further research on selected parameters in those aged 65 years than in those aged 50 years. However, expected value of partial perfect information values for 21-valent pneumococcal conjugate vaccine serotype incidence was substantially lower in both age groups, supporting adult 21-valent pneumococcal conjugate vaccine use regardless of serotype uncertainty.
引用
- Wateska AR, Altawalbeh SM, Nowalk MP, et al. Impact of Serotype Uncertainty on Adult Pneumococcal Vaccine Options: A Value of Information Analysis. Am J Prev Med. 2026. PMID: 41739033. doi:10.1016/j.amepre.2025.108157
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。